Pyr3 inhibits cell viability and PKCα activity to suppress migration in human bladder cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Calcium Signaling

Background:

• Bladder cancer exhibits high recurrence and lethality, with TRPC3 channels influencing cancer cell behavior via calcium signaling.
• Understanding TRPC3's role is crucial for developing targeted bladder cancer therapies.

Purpose of the Study:

• To investigate the effects of the TRPC3 inhibitor Pyr3 and TRPC3 knockdown on muscle-invasive (T24) and non-muscle-invasive (RT4) bladder cancer cells.
• To elucidate the underlying molecular mechanisms, including protein kinase C alpha (PKCα) and protein phosphatase 2A (PP2A) signaling pathways.

Main Methods:

• Treatment of T24 and RT4 bladder cancer cells with Pyr3 and siTRPC3.
• Assessment of cell viability, migration, adhesion, and intracellular calcium influx.
• Western blot analysis to evaluate protein levels of TRPC3, PKCα, phospho-PKCα, and PP2A.
• In vivo xenograft model using T24 cells to assess Pyr3's therapeutic potential.

Main Results:

• Pyr3 treatment significantly reduced bladder cancer cell viability, migration, adhesion, and calcium influx.
• Pyr3 and siTRPC3 downregulated PKCα, phospho-PKCα, and PP2A protein levels.
• In vivo, Pyr3 suppressed tumor growth, viability, and expression of key markers including TRPC3 and phospho-PKCα.
• Phorbol 12-myristate 13-acetate (PMA) could not rescue Pyr3-induced viability loss but reversed migration inhibition, indicating pathway specificity.

Conclusions:

• Pyr3 effectively inhibits bladder cancer cell migration and viability through modulation of calcium signaling and PKC pathways.
• Pyr3 demonstrates potential as a therapeutic agent for bladder cancer, particularly by targeting TRPC3-mediated signaling.
• Further research into Pyr3's mechanisms and efficacy is warranted for clinical application in bladder cancer treatment.